Food, Drugs, Healthcare, Life Sciences

On February 23, 2026, the Food and Drug Administration (FDA) released a draft guidance entitled "Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized...

On February 6, 2026, the US Food and Drug Administration (FDA) announced its intent to take action against compounded GLP-1 medications.

Artificial intelligence is no longer a peripheral tool in personalized medicine. AI is becoming a central driver of how diagnostics...

On February 6, 2026, the US Food and Drug Administration (FDA) announced its intent to take action against compounded GLP-1 medications.

The Centers for Medicare & Medicaid Services ("CMS") unveiled the Long-term Enhanced Accountable Care Organization ("ACO") Design ("LEAD") model, which aims to expand provider participation...

On February 20, 2026, the Department of Justice's Antitrust Division (DOJ) and Ohio Attorney General (Ohio AG) sued OhioHealth Corporation (OhioHealth), alleging that OhioHealth had unlawfully restrained trade in the market for general acute care inpatient hospital services in the Columbus area in violation of the Sherman Act and Ohio's antitrust statute (the Valentine Act).

On February 6, 2026, the US Food and Drug Administration (FDA) announced its intent to take action against compounded GLP-1 medications.

The Centers for Medicare & Medicaid Services ("CMS") unveiled the Long-term Enhanced Accountable Care Organization ("ACO") Design ("LEAD") model, which aims to expand provider participation...

The California Air Resources Board (CARB) is currently gathering data for its Technical Assessment for Personal Fragrance Products (PFPs).